LDS/Medical Tests/Epstein-Barr Virus (EBV) VCA, IgG

Epstein-Barr Virus (EBV) VCA, IgG

The Epstein-Barr virus (EBV) is one of the eight known herpes viruses and is the most common. It is transmitted by close contact with the saliva of an infected individual and is not known to be transmitted through the air. In the U.S., more than 90% of adults over the age of 35 will become infected with asymptomatic EBV and will test positive for the antibody. Some research suggests that EBV is possibly responsible for “chronic fatigue syndrome,” but this has not been confirmed. In teenagers and young adults, EBV can clinically manifest as infectious mononucleosis, which causes a variety of symptoms including fever, fatigue, sore throat, and swollen lymph nodes. Even though these symptoms typically resolve themselves after a few weeks, the virus will remain dormant in certain cells for life. In rare cases, the dormant virus may reactivate and play a role in more serious diseases such as Burkitt’s lymphoma or nasopharyngeal carcinoma.

The treatment for EBV infections is supportive and treats only the symptoms. Infectious mononucleosis can last up to 4 months, but will always resolve and is never fatal. When symptoms are present, a rapid screening test for infectious mononucleosis (“mono spot”) will be performed. If this test is negative, antibodies to EBV should be sought, including IgG and IgM to the viral capsid antigen (anti-VCA), EBV early antigen (anti-EA) and EBV nuclear antigen (anti-EBNA). Early testing for EBV usually involves detection of the viral capsid antigen (VCA). IgG to the viral capsid antigen appears in the acute phase when the level of antibody peaks about 2 weeks after onset of the disease. It declines over time but will always remain detectable. IgM to the viral capsid antigen appears early but returns to undetectable levels after 4 to 6 weeks. IgG to the early antigen will also appear within 2-4 weeks after onset but does not remain present after approximately 3 to 6 months. EBNA is not present in early onset and appears after about 2 months and remains detectable for life. EBV antibodies can be present in healthy individuals; therefore diagnosis of an EBV infection should be made by a physician who can correlate clinical symptoms and laboratory testing.

  • Aid in the diagnosis of acute or late stage EBV infection
  • Differential diagnosis of past EBV infection
  • As an aid in diagnosis of infectious mononucleosis
  • As an aid in diagnosis of Burkitt's lymphoma
  • As an aid in diagnosis of nasopharyngeal carcinoma
  • As an aid in diagnosis of chronic fatigue syndrome

Positive in:

  • Infectious mononucleosis
  • Burkitt lymphoma
  • Nasopharyngeal carcinoma
  • Lymphoproliferative disorders
  • Past EBV infection

Negative in:

  • Usually negative in intital/early acute infection
Index Value Interpretation
<0.9 No detectable IgG antibodies to EBV VCA.
0.91-1.09 Equivocal results – testing should be repeated in 1-2 weeks.
>1.10 Reactive for IgG antibodies to EBV VCA.

Immunoassay, Enzyme-Linked Immunosorbent Assay (ELISA). 

Serum (SST).

Stability

  • Ambient: 48 hours
  • Refrigerated: 7 days
  • Frozen: 60 days
CBC with differential, ESR, Mono spot test, EBV viral capsid antigen IgG, EBV viral capsid antigen IgM, EBV nuclear antigen, EBV by PCR, CMV serology, HSV 1 and 2 IgG, VZV IgG.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Virus Res. 2002 Jan 30;82(1-2):109-13. [PMID: 11885937]
  • Am Fam Physician. 2004;70:1279. [PMID: 15508538]
  • Annu Rev Pathol. 2006;1:375-404. [PMID: 18039120]
  • Lancet Infect Dis. 2003 Mar;3(3):131-40. [PMID: 12614729]
  • Am J Med. 2007 Oct;120(10):911.e1-8. [PMID: 17904463]
  • In Vivo. 2007 Sep-Oct;21(5):707-13. [PMID: 18019402]
  • Clin Otolaryngol Allied Sci. 2001 Feb;26(1):3-8. [PMID: 11298158]
  • Stevens, Christine Dorresteyn. Clinical Immunology & Serology A Laboratory Perspective 3rd edition. Philadelphia: F.A. Davis Company (2010).
  • EBV early antigen (EA) ELISA II package insert. Wampole laboratories ref. 425000CE 06/2005. Epstein Barr Virus and Infectious Mononucleosis. (2006, May 16). Retrieved August 28, 2010, from Center for Disease Control: http://www.cdc.gov/ncidod/diseases/ebv.htm
  • Betty Forbes. (2007). Bailey & Scott's Diagnostic Microbiology. St. Louis: Mosby Elsevier.